Conversations in Drug Development Trends

MAY 30, 2024

This approach is facilitated by developing ASOs and RNA interference (RNAi) therapies, which target the various molecular and genetic mechanisms contributing to ALS pathophysiology and disease progression. The post Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies appeared first on Worldwide Clinical Trials.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

The Strateos Blog: Drug Discovery

DECEMBER 13, 2021

Senior Director, R&D Strategy, will be delivering a presentation highlighting how Strateos' smart lab platform accelerated riboswitch engineering to develop novel biosensors. Learn how Strateos’ automated synthetic biology modules supported rapid, iterative screening of RNA sequences in modular pbuE expression system and E.

Engineering 52

Engineering Protein Expression Research Laboratories RNA 52

Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context. DNA vectors in mouse models?

Therapies 59

Therapies RNA Protein Expression DNA 59

DrugBank

JULY 24, 2024

Additionally, while small molecules can target well-defined pockets on enzymes or receptors, targeting PPIs presents a unique challenge due to their flat, featureless interfaces and large interaction areas. Despite these challenges, the progress in PPI-modulating drugs is noteworthy.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

The Pharma Data

AUGUST 16, 2021

The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Broad Institute

OCTOBER 4, 2023

Today, scientists use such reactions to produce the customizable DNA and RNA molecules that enable genetic sequencing, drug and vaccine development, pathogen tests, cancer diagnostics, and more. Wang concluded her presentation by expressing gratitude to Merkin.

DNA 52

DNA RNA Science Protein Expression 52

Alta Sciences

APRIL 17, 2024

Oligonucleotide-Based Techniques Most oligonucleotide therapies act through antisense mechanisms and are directed against various RNA species. They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52